Galectin-9 suppresses the proliferation of gastric cancer cells in vitro

Oncology Reports

Volumn 35, Issue 2, 2016, Pages 851-860

  Takano, Jitsuko ^a   Morishita, Asahiro ^a   Fujihara, Shintaro ^a   Iwama, Hisakazu ^b   Kokado, Fuyuko ^a   Fujikawa, Keiko ^a   Fujita, Koji ^a   Chiyo, Taiga ^a   Tadokoro, Tomoko ^a   Sakamoto, Teppei ^a   Nomura, Takako ^a   Tani, Joji ^a   Miyoshi, Hisaaki ^a   Yoneyama, Hirohito ^a   Kobara, Hideki ^a   Mori, Hirohito ^a   Niki, Toshihiro ^a   Hirashima, Mitsuomi ^a   Masaki, Tsutomu ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b Life Science Research Center   (Japan)

Author keywords

Caspase cleaved keratin 18; Galectin 9 apoptosis; Gastric cancer; Insulin like growth factor 1 receptor angiogenesis; MicroRNAs

Indexed keywords

BETA GALACTOSIDASE; CASPASE CLEAVED KERATIN 18; CYTOKERATIN; ECALECTIN; INTERLEUKIN 8; MICRORNA; PROTEIN TYROSINE KINASE; RANTES; SOMATOMEDIN C; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 3; GALECTIN; LGALS9 PROTEIN, HUMAN;

ANGIOGENESIS; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DENSITOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; GASTRIC CANCER CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; STOMACH CANCER; UPREGULATION; DNA MICROARRAY; DRUG EFFECTS; PATHOLOGY; PHYSIOLOGY; STOMACH TUMOR; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GALECTINS; HUMANS; IN VITRO TECHNIQUES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; STOMACH NEOPLASMS;

EID: 84954289320     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.4452     Document Type: Article

References (41)

1. Bray F, Jemal A, Grey N, Ferlay J and Forman D: Global cancer transitions according to the Human Development Index (2008-2030): A population-based study. Lancet Oncol 13: 790-801, 2012.
2. Lordick F and Siewert JR: Recent advances in multimodal treatment for gastric cancer: A review. Gastric Cancer 8: 78-85, 2005.
3. Bilici A: Treatment options in patients with metastatic gastric cancer: Current status and future perspectives. World J Gastroenterol 20: 3905-3915, 2014.
4. Thijssen VL, Heusschen R, Caers J and Griffioen AW: Galectin expression in cancer diagnosis and prognosis: A systematic review. Biochim Biophys Acta 1855: 235-247, 2015.
5. Wiersma VR, de Bruyn M, Helfrich W and Bremer E: Therapeutic potential of galectin-9 in human disease. Med Res Rev 33 (Suppl 1): E102-E126, 2013.
6. Fujihara S, Mori H, Kobara H, Rafiq K, Niki T, Hirashima M and Masaki T: Galectin-9 in cancer therapy. Recent Pat Endocr Metab Immune Drug Discov 7: 130-137, 2013.
7. Hirashima M: Ecalectin/galectin-9, a novel eosinophil chemoattractant: Its function and production. Int Arch Allergy Immunol 122 (Suppl 1): 6-9, 2000.
8. Matsumoto R, Matsumoto H, Seki M, Hata M, Asano Y, Kanegasaki S, Stevens RL and Hirashima M: Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes. J Biol Chem 273: 16976-16984, 1998.
9. Matsushita N, Nishi N, Seki M, Matsumoto R, Kuwabara I, Liu FT, Hata Y, Nakamura T and Hirashima M: Requirement of divalent galactoside-binding activity of ecalectin/galectin-9 for eosinophil chemoattraction. J Biol Chem 275: 8355-8360, 2000.
10. Saita N, Goto E, Yamamoto T, Cho I, Tsumori K, Kohrogi H, Maruo K, Ono T, Takeya M, Kashio Y, et al: Association of galectin-9 with eosinophil apoptosis. Int Arch Allergy Immunol 128: 42-50, 2002.
11. Asakura H, Kashio Y, Nakamura K, Seki M, Dai S, Shirato Y, Abedin MJ, Yoshida N, Nishi N, Imaizumi T, et al: Selective eosinophil adhesion to fibroblast via IFN-gamma-induced galectin-9. J Immunol 169: 5912-5918, 2002.
12. Kageshita T, Kashio Y, Yamauchi A, Seki M, Abedin MJ, Nishi N, Shoji H, Nakamura T, Ono T and Hirashima M: Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance. Int J Cancer 99: 809-816, 2002.
13. Kobayashi T, Kuroda J, Ashihara E, Oomizu S, Terui Y, Taniyama A, Adachi S, Takagi T, Yamamoto M, Sasaki N, et al: Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways. Leukemia 24: 843-850, 2010.
14. Kuroda J, Yamamoto M, Nagoshi H, Kobayashi T, Sasaki N, Shimura Y, Horiike S, Kimura S, Yamauchi A, Hirashima M, et al: Targeting activating transcription factor 3 by galectin-9 induces apoptosis and overcomes various types of treatment resistance in chronic myelogenous leukemia. Mol Cancer Res 8: 994-1001, 2010.
15. Fujita K, Iwama H, Sakamoto T, Okura R, Kobayashi K, Takano J, Katsura A, Tatsuta M, Maeda E, Mimura S, et al: Galectin-9 suppresses the growth of hepatocellular carcinoma via apoptosis in vitro and in vivo. Int J Oncol 46: 2419-2430, 2015.
16. Kobayashi K, Morishita A, Iwama H, Fujita K, Okura R, Fujihara S, Yamashita T, Fujimori T, Kato K, Kamada H, et al: Galectin-9 suppresses cholangiocarcinoma cell proliferation by inducing apoptosis but not cell cycle arrest. Oncol Rep 34: 1761-1770, 2015.
17. Nishi N, Itoh A, Fujiyama A, Yoshida N, Araya S, Hirashima M, Shoji H and Nakamura T: Development of highly stable galectins: Truncation of the linker peptide confers protease-resistance on tandem-repeat type galectins. FEBS Lett 579: 2058-2064, 2005.
18. Schutte B, Henfling M, Kölgen W, Bouman M, Meex S, Leers MP, Nap M, Björklund V, Björklund P, Björklund B, et al: Keratin 8/18 breakdown and reorganization during apoptosis. Exp Cell Res 297: 11-26, 2004.
19. Masaki T, Tokuda M, Yoshida S, Nakai S, Morishita A, Uchida N, Funaki T, Kita Y, Funakoshi F, Nonomura T, et al: Comparison study of the expressions of myristoylated alanine-rich C kinase substrate in hepatocellular carcinoma, liver cirrhosis, chronic hepatitis, and normal liver. Int J Oncol 26: 661-671, 2005.
20. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
21. Hartgrink HH, Jansen EP, van Grieken NC and van de Velde CJ: Gastric cancer. Lancet 374: 477-490, 2009.
22. Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137-2150, 2006.
23. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
24. Abe N, Watanabe T, Suzuki K, Machida H, Toda H, Nakaya Y, Masaki T, Mori T, Sugiyama M and Atomi Y: Risk factors predictive of lymph node metastasis in depressed early gastric cancer. Am J Surg 183: 168-172, 2002.
25. Yamaguchi T, Sano T, Katai H, Sasako M and Maruyama K: Node-positive mucosal gastric cancer: A follow-up study. Jpn J Clin Oncol 31: 153-156, 2001.
26. de Manzoni G, Verlato G, di Leo A, Guglielmi A, Laterza E, Ricci F and Cordiano C: Perigastric lymph node metastases in gastric cancer: Comparison of different staging systems. Gastric Cancer 2: 201-205, 1999.
27. Jiang J, Jin MS, Kong F, Cao D, Ma HX, Jia Z, Wang YP, Suo J and Cao X: Decreased galectin-9 and increased Tim-3 expression are related to poor prognosis in gastric cancer. PLoS One 8: e81799, 2013.
28. Yang J, Zhu L, Cai Y, Suo J and Jin J: Role of downregulation of galectin-9 in the tumorigenesis of gastric cancer. Int J Oncol 45: 1313-1320, 2014.
29. Yokozaki H: Molecular characteristics of eight gastric cancer cell lines established in Japan. Pathol Int 50: 767-777, 2000.
30. Motoyama T, Hojo H and Watanabe H: Comparison of seven cell lines derived from human gastric carcinomas. Acta Pathol Jpn 36: 65-83, 1986.
31. Kramer G, Erdal H, Mertens HJ, Nap M, Mauermann J, Steiner G, Marberger M, Bivén K, Shoshan MC and Linder S: Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 64: 1751-1756, 2004.
32. Morishita A, Gong J and Masaki T: Targeting receptor tyrosine kinases in gastric cancer. World J Gastroenterol 20: 4536-4545, 2014.
33. Hilmi C, Larribere L, Giuliano S, Bille K, Ortonne JP, Ballotti R and Bertolotto C: IGF1 promotes resistance to apoptosis in melanoma cells through an increased expression of BCL2, BCL-X(L), and survivin. J Invest Dermatol 128: 1499-1505, 2008.
34. Numata K, Oshima T, Sakamaki K, Yoshihara K, Aoyama T, Hayashi T, Yamada T, Sato T, Cho H, Shiozawa M, et al: Clinical significance of IGF1R gene expression in patients with stage II/III gastric cancer who receive curative surgery and adjuvant chemotherapy with S-1. J Cancer Res Clin Oncol: Sep 3, 2015 (Epub ahead of print). http://dx.doi.org/10.1007/s00432-015-2039-6.
35. Galamb O, Sipos F, Molnar B, Szoke D, Spisak S and Tulassay Z: Evaluation of malignant and benign gastric biopsy specimens by mRNA expression profile and multivariate statistical methods. Cytometry B Clin Cytom 72: 299-309, 2007.
36. Ge J, Chen Z, Wu S, Chen J, Li X, Li J, Yin J and Chen Z: Expression levels of insulin-like growth factor-1 and multidrug resistance-associated protein-1 indicate poor prognosis in patients with gastric cancer. Digestion 80: 148-158, 2009.
37. Yamada S, Kato S, Matsuhisa T, Makonkawkeyoon L, Yoshida M, Chakrabandhu T, Lertprasertsuk N, Suttharat P, Chakrabandhu B, Nishiumi S, et al: Predominant mucosal IL-8 mRNA expression in non-cagA Thais is risk for gastric cancer. World J Gastroenterol 19: 2941-2949, 2013.
38. Lee KH, Bae SH, Lee JL, Hyun MS, Kim SH, Song SK and Kim HS: Relationship between urokinase-type plasminogen receptor, interleukin-8 gene expression and clinicopathological features in gastric cancer. Oncology 66: 210-217, 2004.
39. Lee KE, Khoi PN, Xia Y, Park JS, Joo YE, Kim KK, Choi SY and Jung YD: Helicobacter pylori and interleukin-8 in gastric cancer. World J Gastroenterol 19: 8192-8202, 2013.
40. Morishita A and Masaki T: miRNA in hepatocellular carcinoma. Hepatol Res 45: 128-141, 2015.
41. Cui ZH, Shen SQ, Chen ZB and Hu C: Growth inhibition of hepatocellular carcinoma tumor endothelial cells by miR-204-3p and underlying mechanism. World J Gastroenterol 20: 5493-5504, 2014.